Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression
by
Baldwin DS, Carabal E.
Mental Health Group, Faculty Of Medicine,
Health and Biological Sciences,
University of Southampton, Southampton, U.K.
Drugs Today (Barc). 1999 Sep;35(9):719-24


ABSTRACT

Reboxetine is a selective noradrenaline reuptake inhibitor that has been found to be efficacious and tolerable in both short- and long-term treatment of depression. It is a racemic mixture of two enantiomers, the (S,S)-enantiomer being the more potent inhibitor. Reboxetine has little effect on 5-HT or dopamine reuptake, does not inhibit monoamine oxidase activity and has low affinity for alpha-adrenergic and muscarinic receptors. Absorption is rapid and the terminal elimination half-life (13 h) allows twice-daily administration. It shows linear pharmacokinetics which are unaffected by multiple dosing, gender or hepatic insufficiency, although doses should be reduced in elderly patients and in those with severe renal impairment. Reboxetine does not interact with the principal isotypes of the cytochrome P450 system and should have a low potential for drug-drug interactions. Studies in animal models indicate that it has low toxicity.


Selectivity
Reboxetine
Venlafaxine
Noradrenaline
Serotonin reuptake inhibition
Dopamine reuptake inhibition
Noradrenaline reuptake inhibition
Noradrenaline, anxiety and mood disorders



Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family